Restoration of Cytotoxic T Lymphocyte Function in Malignant Pleural Effusion: Interleukin-15 vs. Interleukin-2
- 1 January 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 20 (1) , 31-39
- https://doi.org/10.1089/107999000312711
Abstract
The present study attempts to define the role of interleukin-15 (IL-15), as compared with IL-2, in generating cytotoxic T lymphocytes (CTL) from the malignant effusions of cancer patients. Effusion-associated lymphocytes (EAL) from malignant effusion were incubated with IL-15 or IL-2 with or without alpha CD3. Proliferation and cytotoxicity assays were performed. IL-15 was found to have at least an equivalent, if not higher, activity to IL-2 in terms of lymphocyte proliferation and generation of CTL from EAL. The proliferative response of EAL, cocultured with IL-15, with or without alpha CD3, was partly inhibited by pretreatment with an anti-IL2 receptor beta chain monoclonal antibody (mAb). The proliferative response of EAL, cocultured with alpha CD3, IL-2, or both, was partly inhibited by pretreatment with an anti-IL-2 receptor alpha chain mAb. Overnight [51Cr] release assays against K562, Daudi, and the patients' autologous tumor cells were done to evaluate EAL's cytolytic activity. MHC class I Ab blocked the stimulated cytolytic activity of EAL against autologous tumors. An mAb depletion assay showed that the phenotype of the restored EAL was CD16-CD4-CD8+; thus, the restored activity of EAL was CTL activity. The results suggest that both IL-15 and IL-2 can restore CTL activity from EAL in the presence of T cell receptor (TCR)-CD3 engagement, but the effect of IL-15 was superior.Keywords
This publication has 17 references indexed in Scilit:
- Interleukin-15 protects from lethal apoptosis in vivoNature Medicine, 1997
- Cross Regulation by IL-10 and IL-2/IL-12 of the Helper T Cells and the Cytolytic Activity of Lymphocytes From Malignant Effusions of Lung Cancer PatientsChest, 1997
- Restoration of the Immunocompetence by IL-2 Activation and TCR-CD3 Engagement of the In Vivo Anergized Tumor-Specific CTL from Lung Cancer PatientsJournal of Immunotherapy, 1997
- Elevation of Interleukin-10 Levels in Malignant Pleural EffusionChest, 1996
- Studies Evaluating the Antitumor Activity and Toxicity of Interleukin-15, a New T Cell Growth Factor: Comparison with Interleukin-2Cellular Immunology, 1995
- Interleukin-15 and the Growth of Tumor Derived Activated T-CellsCancer Biotherapy, 1995
- Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.The Journal of Experimental Medicine, 1994
- Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 ReceptorScience, 1994
- The PleuraAmerican Review of Respiratory Disease, 1988
- Monoclonal Antibodies Defining Distinctive Human T Cell Surface AntigensScience, 1979